Trends of Systemic Therapy Use for Renal Cell Carcinoma in the United States

摘要

OBJECTIVE To assess the utilization of immunotherapy after the advent of tyrosine-kinase inhibitors and mammalian target of rapamycin inhibitors for metastatic renal cell carcinoma (RCC) in the United States, as well as to better understand the variables associated with the implementation of these systemic therapies.